The Journey of Cyclosporine

Cyclosporine is a neutral, highly lipophilic cyclic peptide (MW
~1,202 Da) originally derived from Tolypocladium inflatum. Its oral bioavailability is highly variable:
the original oil-based formulation (Sandimmune) has bioavailability of 20-50% depending on bile
flow and diet; the microemulsion preconcentrate (Neoral, Gengraf) has improved and more consistent
bioavailability of 30-60% with a narrower inter-patient variability. Peak plasma concentrations
are achieved within 1.5-2 hours after the microemulsion formulation, but with wide inter-patient
and intra-patient variability. Oral absorption depends critically on bile acids (bile-acid sequestrants,
cholestyramine, and gut inflammation/diarrhea dramatically reduce absorption). Food with high fat
content increases absorption with Sandimmune but not Neoral. Bioequivalence between formulations
is not guaranteed — dose adjustment and TDM are required when switching.

Cyclosporine distributes extensively in tissues with a volume of
distribution of approximately 3-5 L/kg (whole blood basis). Critically, approximately 40-60% of
cyclosporine in whole blood is concentrated in erythrocytes (temperature-dependent association),
with 10-20% in leukocytes and lymphocytes, and 30% in plasma. Of the plasma fraction, 90% is
protein-bound to lipoproteins (VLDL, LDL, HDL) and albumin. Because red blood cell distribution
is temperature- and hematocrit-dependent, cyclosporine concentrations must be measured in EDTA
whole blood at a standardized temperature. The drug penetrates well into lymphoid tissue, liver,
kidney, heart, and lungs — all target organs for both therapeutic effect and toxicity. CNS
penetration is limited.

Cyclosporine binds to cyclophilin A (PPIA), a cytoplasmic
peptidyl-prolyl isomerase abundantly expressed in all cells including T lymphocytes. The cyclosporine-
cyclophilin complex then binds and inhibits calcineurin (protein phosphatase 2B, PP2B) — a calcium-
and calmodulin-dependent serine-threonine phosphatase. In T cell activation, antigen stimulation
raises cytoplasmic calcium, activating calcineurin, which dephosphorylates nuclear factor of
activated T cells (NFAT) family transcription factors (NFATC1-4). Dephosphorylated NFAT
translocates to the nucleus and activates transcription of IL-2, IL-4, IL-13, TNF-α, and other
cytokines that drive T cell proliferation and clonal expansion. By blocking calcineurin, cyclosporine
prevents NFAT dephosphorylation and nuclear import, selectively suppressing T cell-mediated
(specifically CD4+ helper and CD8+ cytotoxic T cell) immune responses without broadly
immunosuppressing innate immunity.

Cyclosporine is extensively metabolized by CYP3A4 and CYP3A5 in
the gut wall and liver to more than 30 known metabolites (AM1-AM25 etc.), all pharmacologically
inactive or with low activity. P-glycoprotein (P-gp/MDR1) in the gut wall effluxes cyclosporine
back into the gut lumen, working in concert with CYP3A4 to limit oral bioavailability and
accelerate first-pass elimination. Drug interactions via CYP3A4 and P-gp are extensive and clinically
critical: CYP3A4/P-gp inhibitors (ketoconazole, fluconazole, diltiazem, verapamil, erythromycin,
grapefruit juice) dramatically increase cyclosporine levels and nephrotoxicity risk; CYP3A4 inducers
(rifampicin, phenytoin, carbamazepine, St. John's Wort) reduce levels and precipitate rejection.
Cyclosporine itself inhibits OATP1B1/1B3 hepatic uptake transporters, substantially increasing
levels of statins (rosuvastatin 7-fold AUC increase), causing rhabdomyolysis risk.

Cyclosporine is eliminated almost entirely by hepatic metabolism
and biliary excretion; less than 1% is excreted unchanged in urine. Approximately 6% of the dose
is recovered in feces as unchanged drug, with the remainder as metabolites. Elimination half-life
is approximately 8-35 hours (wide variability due to CYP3A4 variability, hematocrit, and
temperature-dependent RBC binding). Routine therapeutic drug monitoring (TDM) — measuring 12-hour
trough concentrations (C0) or 2-hour post-dose concentrations (C2) in whole blood — is mandatory
for all patients on cyclosporine. Target trough levels vary by indication and transplant type
(early post-transplant: 200-400 ng/mL for kidney; maintenance: 50-150 ng/mL). Severe hepatic
impairment substantially reduces elimination, requiring dose reduction. Renal impairment does not
significantly alter pharmacokinetics but increases end-organ sensitivity to nephrotoxicity.

Cyclosporine transformed organ transplantation — before its introduction
in the 1980s, one-year kidney transplant survival was approximately 50%; cyclosporine brought it
to >80%. It is used for prevention and treatment of organ rejection (kidney, liver, heart, lung,
pancreas), GVHD in bone marrow transplantation, rheumatoid arthritis, plaque psoriasis, and
nephrotic syndrome. Nephrotoxicity (acute and chronic — the latter causing progressive interstitial
fibrosis and tubular atrophy) is the most clinically significant adverse effect, limiting long-term
use. Hypertension, hyperkalemia, hypomagnesemia, hirsutism, gingival hyperplasia, and neurotoxicity
(tremor, seizures) are other adverse effects. Tacrolimus has largely replaced cyclosporine for many
transplant indications due to lower nephrotoxicity at equivalent efficacy.